Medications That Cause Ecchymoses
Multiple drug classes can cause ecchymoses, most notably antiplatelet agents (aspirin and clopidogrel), anticoagulants (warfarin, enoxaparin), SSRIs (sertraline, fluoxetine), and certain biologics (bevacizumab, erenumab).
Primary Culprits
Antiplatelet and Anticoagulant Therapy
Ecchymosis is a well-recognized complication of antiplatelet therapy, particularly in patients receiving aspirin (ASA) or dual antiplatelet therapy with clopidogrel 1. These medications impair platelet function, leading to increased bruising susceptibility. When ecchymosis develops in patients on antiplatelet therapy, obtain a complete blood count, INR, and aPTT to rule out thrombocytopenia or coagulopathy 1. If these tests are normal, antiplatelet drugs can be safely continued.
Low molecular weight heparins like enoxaparin commonly cause ecchymosis and hematoma formation at injection sites 2. The abdomen is preferable to the arm for subcutaneous administration, as it results in smaller hematomas after 72 hours 2.
Selective Serotonin Reuptake Inhibitors (SSRIs)
SSRIs represent an increasingly recognized cause of ecchymoses through their effect on platelet serotonin uptake, which impairs platelet aggregation. Sertraline and fluoxetine have been documented to cause significant ecchymosis even in the absence of trauma, bleeding disorders, or abnormal coagulation studies 3, 4. The causality is well-established, with symptoms resolving after drug discontinuation 3.
Biologic Agents
Bevacizumab (anti-VEGF monoclonal antibody) has been associated with multiple cutaneous ecchymoses 5. Erenumab (CGRP receptor antibody) may cause increased bruising tendency, particularly when combined with fish oil supplements, likely through impaired wound healing rather than direct platelet effects 6.
Clinical Approach
Risk Factors for Increased Bleeding
- Concurrent anticoagulant therapy (warfarin or heparin)
- Systemic corticosteroid use
- Chronic renal or hepatic disease
- Thrombocytopenia
- Concomitant use of fish oil supplements (especially with biologics) 6
When to Investigate Further
Petechiae (pinpoint hemorrhages) in antiplatelet-treated patients warrant immediate investigation for thrombocytopenia 1. This is distinct from simple ecchymosis and suggests more serious hematologic compromise.
Management Algorithm
- Document medication history including antiplatelet agents, anticoagulants, SSRIs, and biologics
- Order laboratory testing: CBC with platelet count, INR, aPTT 1
- If labs are normal: Continue necessary medications (antiplatelet/anticoagulant therapy) but consider discontinuing SSRIs or non-essential agents causing symptoms 3
- If thrombocytopenia or coagulopathy present: Address underlying cause before continuing offending agents
Important Caveats
The combination of multiple bleeding-risk medications exponentially increases ecchymosis risk. Patients on dual antiplatelet therapy plus SSRIs represent a particularly high-risk group, though this specific interaction is not well-studied in the literature.
Minor bleeding and ecchymosis are generally self-limiting and do not require drug discontinuation for essential cardiovascular medications 1. However, SSRIs can be discontinued or switched to alternative antidepressants if ecchymosis is bothersome or extensive 3, 4.
Fish oil supplements, while not medications per se, significantly potentiate bruising when combined with biologics like erenumab and should be discontinued if excessive ecchymosis develops 6.